

HPAP-082 Donor Summary



HPAP	082	UNOS		
Recovery OPO	OHLB - Lifebanc	Allocation Via	UPENN <input type="checkbox"/> nPOD <input checked="" type="checkbox"/>	
Age (years)	25	DCD	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>	
Race	White	DBD	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>	
Sex	M <input checked="" type="checkbox"/> F <input type="checkbox"/>	Admission to Cross Clamp	333 Hours 23 Mins.	
ABO (Rh)	O+	Cross Clamp Time	01/28/2021 19:48EST	
BMI (Kg/m²)	23.959	Cold Ischemia Time*	17Hours 18Mins. WIT 18minutes	
Weight (kg)	82			
Height (cm)	185			
Cause of Death	Head Trauma	Preservation Solution	UW <input checked="" type="checkbox"/> HTK <input type="checkbox"/>	
Mechanism of Injury	Blunt Injury	Organs Recovered	Heart <input type="checkbox"/> Lung <input type="checkbox"/> Liver <input type="checkbox"/>	Kidney <input checked="" type="checkbox"/> Pancreas <input checked="" type="checkbox"/> Intestine <input type="checkbox"/>
Cardiac Arrest/Downtime	Yes <input checked="" type="checkbox"/> 0 minutes No <input type="checkbox"/>	Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:	<input type="text"/> Hours <input type="text"/> Mins. N/A	
CPR / Time	Yes <input checked="" type="checkbox"/> 0 minutes No <input type="checkbox"/>	Organs Discarded	Heart <input type="checkbox"/> Lung <input type="checkbox"/> Liver <input type="checkbox"/>	Kidney <input type="checkbox"/> Pancreas <input type="checkbox"/> Intestine <input type="checkbox"/>
Total Est. Downtime	Likely less than 5 minutes	Blood Culture	No Growth	
Date /Time of Admission	01/14/2021 22:25EST	PHS High Risk	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>	
		Acute Lung Injury	Bibasilar infiltrate, possible small bilateral pleural effusions	

*Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.



HPAP-082 Donor Summary

Medical History:

		Duration	Medications	Compliance
Type of Diabetes	-----	-----	-----	-----
History of cancer	-----	-----	-----	-----
CAD	-----	-----	-----	-----
Hypertension	-----	-----	-----	-----
Hyperlipidemia	-----	-----	-----	-----
Autoimmune disease	-----	-----	-----	-----
Family History	CAD <input type="checkbox"/>	Diabetes <input checked="" type="checkbox"/>	Auto immune disease <input type="checkbox"/>	Others:
Surgical History:	None			
Comments:	(M) Great grandmother and(m) great aunt IDDM, (M) grandmother NIDDM, Smoking Hx: Vaping daily since age 20; Chewing tobacco from age 16-24 Etoh Hx: Beer 2 cans daily x 3 years Drug Hx Marijuana frequency & time frame unknown; Acid 1-2 times as teenager			

Hemodynamic Profile

Average BP During Hospitalization (mmHg)	131/77	
Average Low BP During Hospitalization	122/67	Duration: 1 H
Average BP in OR (mmHg)	NA	
Average Low BP in OR (mmHg)	NA	Duration:
Average HR in OR (bpm)	NA	
ABG-pH range	7.24 – 7.54	

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	275	3	725
PRBCs	350	3	1050
Platelets	50	1	50
Norepinephrine (Levophed)	----	4-10Mcg/min started 14 days before organ recovery for the duration of 5.5	
Vasopressin	----	----	----
Neo-Syneprine	----	----	----
Epinephrine	----	----	----
Phenylephrine	----	----	----
Dopamine	----	----	----



HPAP-082 Donor Summary

Blood Products/Meds Transfused Intraoperative

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	N/A	N/A	N/A
PRBCs	N/A	N/A	N/A
Platelets	N/A	N/A	N/A
Norepinephrine (Levophed)	N/A	N/A	N/A
Vasopressin	N/A	N/A	N/A
Neo-Syneprine (phenylephrine)	N/A	N/A	N/A
Epinephrine	N/A	N/A	N/A
Dopamine	N/A	N/A	N/A
Heparin	N/A	N/A	N/A

Initial Autoantibody Screening (nPOD): ELISA

GAD-65	IA-2
Positive	Negative

Confirmatory results: Radioimmuno Assay (RIA)

	GAD-65 (unit/ml)	IA-2 (unit/ml)	Insulin AAB (unit/ml)	ZnT8 (unit/ml)
Results	0	1	-0.005	-0.003
Cut-off values	20	5	0.010	0.020

*Sample obtained at time of organ recovery.

	C-peptide (ng/ml)	Proinsulin
Results	2.7	-----

*Sample obtained at time of organ recovery.

HLA (OPO)*

Class 1	A	2	3	Class II	DR	1	15
	B	7	62		DR51	51	N-Negative
	C	10	07		DR52	N-Negative	N-Negative
	Bw4	Negative			DR53	N-Negative	N-Negative
	Bw6	Positive			DQB1	5	6
					DQA1	01	01
			DPB1	04:01	04:01		
Comment:							

HPAP-082 Donor Summary



Confirmatory HLA (UPENN)*

Class 1	A	02:01	03:01	Class II	DRB1	01:01	15:01
	B	07:02	15:01		DRB3	----	----
	C	03:04	07:02		DRB4	----	----
					DRB5	01:01	----
					DQB1	05:01	06:02
					DQA1	01:01	01:02
					DPB1	04:01	----
					DPA1	01:03	----

*HLA typing performed using NGS

Infectious Disease Serology

Test	Result	Hemo/Plasma Dilution Status	
		Qualified	Non-Qualified
EBV IgG	Positive	✓	----
EBV IgM	Negative	✓	----
CMV	Negative	✓	----
HBcAb	Negative	✓	----
HBsAg	Negative	✓	----
HCV Ab	Negative	✓	----
HIV I/II	Negative	✓	----
Syphilis	Negative	✓	----
Procleix Ultrio	Nonreactive	✓	----
Ultrio HBV (HBV NAT)	Negative	✓	----
Ultrio HCV (HCV NAT)	Negative	✓	----
Ultrio HIV (HIV NAT)	Negative	✓	----
Toxoplasma Ab	Negative	✓	----
SARS-CoV-2	Negative	✓	----

HPAP-082 Donor Summary



Laboratory Panel

	Initial	Peak	Terminal
Na (mEq/L) (135-145)	137	151	151
Creatinine (<1.5)	1.03	1.03	0.61
Glucose (mg/dL) (60-150)	283	183	139
HbA1C%	5.6	----	----
Total bilirubin (0-1.0)	0.4	0.7	0.7
SGOT (AST) (0-40)	46	46	42
SGPT (ALT) (5-35)	33	33	30
Alkaline phosphatase (45-110)	61	104	104
Serum Amylase (23-851)	----	----	214
Serum Lipase (0-80)	----	----	1421
WBC (THO/uL) (4.5-11.0)	13.3	19.9	14.8
Hgb (g/dL) (12-16)	13.4	13.4	8.4
Platelets (THO/uL) (150-350)	336	342	342
INR (<2.0)	1.2	1.4	1.4

Urinalysis

	1 st	2 nd	3 rd	4 th
Glucose	Negative	Negative	Negative	Negative

Medications During Hospitalization

Steroids**	-----
Diuretics	-----
T3 Protocol	-----
T4 Protocol*	-----
Insulin**	-----
Antihypertensive	-----
Vasodilators	-----
DDAVP**	-----
Total parenteral nutrition	-----
Other	Keppra, Labetalol, Hydralazine, Zosyn, Lovenox
	Specify

*T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015;7 17-27.

** Excluding T4 Protocol